Gold Member Since 2015
Audited Supplier
Zhuhaishi Shuangbojie Technology Co., Ltd.

Gdf-8, Myostatin, Peptide manufacturer / supplier in China, offering 99% Purity Best Quality Pharmaceutical Bodybuilding Peptide Gdf-8, Injectable Muscle Mass Gain and Cutting Steroid Boldenone Undecylenate/ Equipoise, Anti Tumor Peptide Leuprolide Acetate 53714-56-0 and so on.

(/ )

Supplier Homepage Product Peptides and human growth steroid 99% Purity Best Quality Pharmaceutical Bodybuilding Peptide Gdf-8

99% Purity Best Quality Pharmaceutical Bodybuilding Peptide Gdf-8

FOB Price: US $1 / Piece
Min. Order: 1 Piece
Min. Order FOB Price
1 Piece US $1/ Piece
Get Latest Price
Production Capacity: 50000kg/Month
Transport Package: as for Customer′s Requirement
Payment Terms: T/T, Western Union, Money Gram

Request a custom order and have something just for you!

Send Customized Request
Basic Info
  • Model NO.: GDF-8
  • Customized: Non-Customized
  • Suitable for: Elderly, Adult
  • Purity: >99%
  • Payment: Western Union, Moneygram, T/T
  • Grade: Natural Plant Extract; Flavors & Fragrances
  • Trademark: Shuangbojie
  • Origin: China
  • Powder: Yes
  • Certification: ISO 9001
  • State: Powder
  • MOQ: 10vials
  • Deivery: Within 24hours After Your Payment
  • Storage: Shading, Confined Preservation
  • Specification: USP/BP
  • HS Code: 123456
Product Description
Myostatin (also known as growth differentiation factor 8, abbreviated GDF-8) is a myokine, a protein produced and released by myocytes that acts on muscle cells' autocrine function to inhibit myogenesis: muscle cell growth and differentiation. In humans it is encoded by the MSTN gene. Myostatin is a secreted growth differentiation factor that is a member of the TGF beta protein family.Animals either lacking myostatin or treated with substances that block the activity of myostatin have significantly more muscle mass. Furthermore, individuals who have mutations in both copies of the myostatin gene have significantly more muscle mass and are stronger than normal. Blocking the activity of myostatin may have therapeutic application in treating muscle wasting diseases such as muscular dystrophy.
 
Product NameGDF 8 Powder 1mg/vial Pharmaceutical Raw Materials High purity GDF-8(myostatin) 
Brand NameLK
Packing1box/10vials,1mg/vial
CAS No901758-09-6
Molecular FormulaC221H366N72O67S
ApplicationPharmaceutical raw materials
purity> 99.0%
 
ItemSpecificationResult
AppearanceWhite powderComplies
IdentificationPositiveComplies
Assay99.0% min99. 3%
Loss on Drying6.0%max.4.80%
Mass Balance 95.0~105.0%Complies
Acetate Content (HPIC)12.0%max.10.80%
Peptide Content (N%)80.0%min.88.00%
Amino Acid Composition±10% of theoreticalComplies
Single Impurity (HPLC)1.0%max.0.85%

Product Description
The human FST gene is comprised of six exons spanning 5329 bp on chromosome 5q11.2 and gives rise to two main transcripts of 1122 bp (transcript variant FST344) and 1386 bp (transcript variant FST317). The first exon encodes the signal peptide, the second exon the N-terminal domain and exons 3-5 each code for a follistatin module. Alternative splicing leads to usage of either exon 6A, which codes for an acidic region in FST344 or exon 6B, which contains two bases of the stop codon of FST317 (Shimasaki et al., 1988).
 
Mature secreted follistatin protein exists in three main forms consisting of 288, 303, and 315 amino acids (Sugino et al., 1993). The FST344 transcript gives rise to a protein precursor of 344 amino acids, which results in the mature 315 amino acid form after removal of the signal peptide. A fraction of follistatin 315 is further converted to the 303 amino acid form by proteolytic cleavage at the C-terminus. Signal peptide removal of FST317 leads to the mature 288 amino acid form of follistatin. All forms of follistatin contain three follistatin domains (FSD) characterized by a conserved arrangement of 10 cysteine residues. The N-terminal subdomains of the FSD have similarity with EGF-like modules, whereas the C-terminal regions resemble the Kazal domains found in multiple serine protease inhibitors. The follistatin protein contains two potential N-glycosilation sites on asparagines 124 and 288.

Usage
The gene encoding myostatin was discovered in 1997 by geneticists Se-Jin Lee and Alexandra McPherron who produced a strain of mutant mice that lack the gene. These myostatin "knockout" mice have approximately twice as much muscle as normal mice. These mice were subsequently named "mighty mice".

Naturally occurring deficiencies of myostatin have been identified in cattle by Ravi Kambadur, whippets, and humans; in each case the result is a dramatic increase in muscle mass. A mutation in the 3' UTR of the myostatin gene in Texel sheep creates target sites for the microRNAs miR-1 and miR-206. This is likely to cause the muscular phenotype of this breed of sheep.

Human myostatin consists of two identical subunits, each consisting of 109 (NCBI database claims human myostatin is 375 residues long) amino acid residues. Its total molecular weight is 25.0 kDa. The protein is inactive until a protease cleaves the NH2-terminal, or "pro-domain" portion of the molecule, resulting in the active COOH-terminal dimer. Myostatin binds to the activin type II receptor, resulting in a recruitment of either coreceptor Alk-3 or Alk-4. This coreceptor then initiates a cell signaling cascade in the muscle, which includes the activation of transcription factors in the SMAD family - SMAD2 and SMAD3. These factors then induce myostatin-specific gene regulation. When applied to myoblasts, myostatin inhibits their differentiation into mature muscle fibers.

Myostatin also inhibits Akt, a kinase that is sufficient to cause muscle hypertrophy, in part through the activation of protein synthesis. However, Akt is not responsible for all of the observed muscle hyperthrophic effects which are mediated by myostatin inhibition Thus myostatin acts in two ways: by inhibiting muscle differentiation, and by inhibiting Akt-induced protein synthesis.

A technique for detecting mutations in myostatin variants has been developed. Mutations that reduce the production of functional myostatin lead to an overgrowth of muscle tissue. Myostatin-related muscle hypertrophy has an incomplete autosomal dominance pattern of inheritance. People with a mutation in both copies of the MSTN gene in each cell (homozygotes) have significantly increased muscle mass and strength. People with a mutation in one copy of the MSTN gene in each cell (heterozygotes) have increased muscle bulk, but to a lesser degree.

In 2004, a German boy was diagnosed with a mutation in both copies of the myostatin-producing gene, making him considerably stronger than his peers. His mother has a mutation in one copy of the gene. An American boy born in 2005 was diagnosed with a clinically similar condition but with a somewhat different cause: his body produces a normal level of functional myostatin; but, because he is stronger and more muscular than most others his age, it is believed that a defect in his myostatin receptors prevents his muscle cells from responding normally to myostatin. He appeared on the television show, World's Strongest Toddler.

Further research into myostatin and the myostatin gene may lead to therapies for muscular dystrophy. The idea is to introduce substances that block myostatin. A monoclonal antibody specific to myostatin increases muscle mass in mice and monkeys.

A two-week treatment of normal mice with soluble activin type IIB receptor, a molecule that is normally attached to cells and binds to myostatin, leads to a significantly increased muscle mass (up to 60%). It is thought that binding of myostatin to the soluble activin receptor prevents it from interacting with the cell-bound receptors.

It remains unclear as to whether long-term treatment of muscular dystrophy with myostatin inhibitors is beneficial, as the depletion of muscle stem cells could worsen the disease later on. As of 2012, no myostatin-inhibiting drugs for humans are on the market. An antibody genetically engineered to neutralize myostatin, stamulumab, which was under development by pharmaceutical company Wyeth., is no longer under development. Some athletes, eager to get their hands on such drugs, turn to the internet where fake "myostatin blockers" are being sold.

Myostatin levels are effectively decreased by creatine supplementation.

Inhibition of myostatin leads to muscle hyperplasia and hypertrophy. Myostatin inhibitors can improve athletic performance and therefore there is a concern these inhibitors might be abused in the field of sports. However, studies in mice suggest that myostatin inhibition does not directly increase the strength of individual muscle fibers.


Grape seed oil
Alias: Vitis vinifera
CAS Registry Number: 8024-22-4
Einecs No: 287-896-9
Grade: Natural Plant Extract; Flavors & Fragrances
Storage: Shading, confined preservation

Description:
Grape seed oil (also called grapeseed oil or grape oil) is pressed from the seeds of grapes, and is thus an abundant by-product of winemaking.

Applications:
Grape seed oil is a preferred cosmetic ingredient for controlling moisture of the skin. Light and thin, grape seed oil leaves a glossy film over skin when used as a carrier oil for essential oils in aromatherapy. It contains more linoleic acid than many other carrier oils. Grape seed oil is also used as a lubricant for shaving. Grape seed oil is also used as a growth and strengthening treatment for hair.

Specifications:
BOTANICAL NAME:Vitis vinifera L
 
PART OF PLANT USED:Seed
 
ORIGIN OF RAW MATERIAL:China
 
COUNTRY OF PROCESSING:China
 
PRODUCT NO.:CPE-ZLGSO0914
 
PHYSICAL/CHEMICALSPECIFICATIONSMethod
APPEARANCELight yellow or green liquid, with grapeseed oil's peculiar smell and tasteSTM 01.010
ACID VALUE, KOH mg /g:≤2.0AOCS Cd 3d-63
PEROXIDE VALUE, meq/kg:≤10.0AOCS Cd 8b-90
SAPONIFICATION VALUE,KOH mg /g:188-194AOCS Cd 3-25
INSOLUBLE IMPURITY, %(m/m):≤0.05AOCS Ca 3a-46
UNSAPONIFIABLE MATTER, %≤2.0AOCS Ca 6a-40
MOISTURE AND VOLATILES, %:≤0.20AOCS Ca 2d-25
GARDNER COLOR≤5AOCS Td 1a-64
COLD TESTClear after 5.5 hours at 0°CAOCS Cc 11-53
RESIDUAL SOLVENT, mg/kg:NegativeAOCS Ba 14-87
LEAD ppm≤0.05AOCS Ca 18c-91
ARSENIC ppm≤0.1AOAC 986.15
CADMIUM ppm≤0.01AOAC 986.15
MERCURY ppm≤0.005AOAC 971.21
FATTY ACID COMPOSITION
 
AOCS Ce 1e-91
C:14:0 MYRISTIC %0-0.3
 
C:16:0 PALMITIC %5.5-11.0
 
C:18:0 STEARIC %3.0-6.5
 
C:18:1 OLEICO %12.0-28.0
 
C:18:2 LINOLEIC %58.0-78.0
 
OTHERS %0-5.0
 

Our advantages:

1. Quality: Our company is a professional production of hormone intermediates for many years, our products have exported to Germany, Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, you can trust us.

2. Payment method: Western Union, MoneyGram, TT.

3. Service: Best service with after-sales service to all clients.

4. Delivery: Package will be shipped with 1days after payment. We can send it via HKems, EMS, HK Air 
Post, DHL or other method. We have a professional and stable logistics, and we can deliver the packagesmoothly around 3 to 5 days.

Our process:
1) Contact me about what you need and your quantity, we will quoted you details.
2) Finish the payment.
3) We will arrange to send parcel out within 1days after payment, when tracking number updates, we will 
email you.
4) Parcel delivered.
Send your message to this supplier
Avatar
Ms. +86 18578209857
*From:
To: Ms. +86 18578209857
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

Find Similar Products By Category